Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei 10617, Taiwan.
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei 10048, Taiwan.
Sensors (Basel). 2017 Nov 26;17(12):2733. doi: 10.3390/s17122733.
Coronary artery disease and its related complications pose great threats to human health. In this work, we aim to clinically evaluate a CMOS field-effect biomolecular sensor for cardiac biomarkers, cardiac-specific troponin-I (cTnI), -terminal prohormone brain natriuretic peptide (NT-proBNP), and interleukin-6 (IL-6). The CMOS biosensor is implemented via a standard commercialized 0.35 μm CMOS process. To validate the sensing characteristics, in buffer conditions, the developed CMOS biosensor has identified the detection limits of IL-6, cTnI, and NT-proBNP as being 45 pM, 32 pM, and 32 pM, respectively. In clinical serum conditions, furthermore, the developed CMOS biosensor performs a good correlation with an enzyme-linked immuno-sorbent assay (ELISA) obtained from a hospital central laboratory. Based on this work, the CMOS field-effect biosensor poses good potential for accomplishing the needs of a point-of-care testing (POCT) system for heart disease diagnosis.
冠状动脉疾病及其相关并发症对人类健康构成了巨大威胁。在这项工作中，我们旨在临床评估一种用于心脏生物标志物的 CMOS 场效应生物分子传感器，包括心肌肌钙蛋白 I（cTnI）、N 端脑利钠肽前体（NT-proBNP）和白细胞介素 6（IL-6）。该 CMOS 生物传感器通过标准商业化的 0.35μm CMOS 工艺实现。为了验证传感特性，在缓冲条件下，所开发的 CMOS 生物传感器确定了 IL-6、cTnI 和 NT-proBNP 的检测极限分别为 45pM、32pM 和 32pM。此外，在临床血清条件下，所开发的 CMOS 生物传感器与医院中心实验室获得的酶联免疫吸附测定（ELISA）具有良好的相关性。基于这项工作，CMOS 场效应生物传感器具有很好的潜力，可以满足心脏病诊断的即时检测（POCT）系统的需求。
